Aislinn Antrim, Managing Editor

Subcutaneous amivantamab demonstrated robust activity in patients with recurrent or metastatic head and neck squamous cell carcinoma previously treated with checkpoint inhibitors and platinum chemotherapy.

The phase 3 trial demonstrated significant improvements in overall and progression-free survival, reinforcing the combination as a standard-of-care option across MMR subgroups.

Long-term findings from the REASSURE study confirm Radium-223’s acceptable hematologic safety profile and reinforce the importance of early use alongside bone-protecting agents to minimize fracture risk and optimize outcomes.

In the ARANOTE trial, darolutamide combined with ADT significantly delayed disease progression and maintained quality of life for patients with metastatic hormone-sensitive prostate cancer, supporting its use as a chemotherapy-free option.

Nicoletta Colombo, MD, PhD, discusses why metronomic chemotherapy dosing and careful regimen design may have driven the success of the KEYNOTE-B96 trial.

At ESMO 2025, Felix Guerrero-Ramos, MD, discussed SunRISe-1 data showing durable responses and low toxicity with TAR-200, the importance of training in device management, and how future biomarker research may refine patient selection and combination strategies.

Andrea Necchi, MD, shared SunRISe-4 primary results demonstrating higher pathologic response and relapse-free survival rates with TAR-200 plus sacituzumab compared with checkpoint inhibitor monotherapy, with no new safety signals observed.

Thor Halfdanarson, MD, discussed early results showing favorable response rates and manageable safety with ^212Pb-VMT-α-NET, along with the role of PET imaging in optimizing patient selection for future trials.

Felix Guerrero-Ramos, MD, outlines molecular and pharmacologic findings from SunRISe-1, including the high prevalence of TP53 alterations and the extended drug exposure achieved with the TAR-200 intravesical delivery system.

Oncologist Thor Halfdanarson reviews dose-finding data for the targeted α radioligand therapy [^212Pb]VMT- α-NET, highlighting manageable toxicity, stable renal function, and plans for phase 2 evaluation.

Recent studies reveal that simvastatin does not enhance escitalopram's effects in treating depression, despite improving metabolic health in obese patients.

With this approval, an effective, nonsteroidal treatment option is available for young patients.

NCCN updated its small-cell lung cancer guidelines, introducing lurbinectedin for maintenance therapy and removing the chemotherapy-free interval for better treatment strategies.

Explore insights into ongoing tensions in the pharmacy industry and their potential impact on competition.

Host Craig Beavers sits down with Lorenz van der Linden, a Belgian pharmacist, to dive deep into 2 groundbreaking trials from the European Society of Cardiology (ESC) 2025 Congress.

Following the European Society of Cardiology Congress 2025, experts gathered to discuss key Hot Line trial data.

Katherine Saunders, MD, weighs in on orforglipron’s potential to expand obesity treatment options, improve adherence with a simple oral regimen, and address barriers to care and access.

Alabama's new law boosts independent pharmacies by ensuring fair PBM reimbursements, while Nevada sets a precedent for expanding pharmacist health care roles.

Experts discuss groundbreaking Hot Line trials at the European Society of Cardiology Congress 2025, offering insights into the latest cardiovascular research.

Explore pharmacy policy updates and insights for July 2025.

Finerenone plays an emerging role in managing complex heart failure with preserved ejection fraction (HFpEF).

The COBBRA trial compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.

Dave’s Pharmacy in Alliance, Nebraska, was named the Pharmacy of the Year for cutting-edge patient care.

Independent pharmacy owners Raj Chhadua and Marc Ost are turning to AI-powered tools to streamline operations, improve efficiency, and enhance patient engagement—without sacrificing the personal touch.

From vaccine drives and prescriber dinners to YouTube education and automated workflows, these pharmacy owners are finding innovative, hands-on ways to expand services, boost revenue, and stay connected to the communities they serve.

Keri Bates, PharmD, shares how the nomination validates years of hard work, highlights the deep relationships built with the community, and inspires continued growth and innovation.

Pharmacy-based clinical services demonstrate both public health impact and financial sustainability.